Anti-Viral Drug Therapy Market Size, Demand, Growth, Analysis and Forecast to 20
Posted by ramacharitbrc on May 20th, 2021
The Anti-Viral Drug Therapy Global Market Report 2021-30 by The Business Research Company describes and explains the global anti-viral drug therapy market and covers 2015 to 2020, termed the historic period, and 2020 to 2025, termed the forecast period, along with further forecasts for the period 2025-2030. The report evaluates the market across each region and for the major economies within each region.
The Anti-Viral Drug Therapy Global Market Opportunities And Strategies Report covers anti-viral drug therapy market drivers, anti-viral drug therapy market trends, anti-viral drug therapy market segments, anti-viral drug therapy market growth rate, anti-viral drug therapy market major players, and anti-viral drug therapy market size.
View Complete Report:
The anti-viral drug therapy market report focuses particularly on identifying the trends, opportunities, and strategies that can lead to success. O&S reports are available off the shelf and can be delivered to clients on the day of purchase.
Anti-Viral Drug Therapy Global Market Opportunities And Strategies Report is the most comprehensive report available on this market and will help gain a truly global perspective as it covers 60 geographies. The chapter on the impact of COVID-19 gives valuable insights on supply chain disruptions, logistical challenges, and other economic implications of the virus on the market. The chapter also covers markets which have been positively affected by the pandemic.
Request For The Sample Now:
Trends in the market include:
Companies in the anti-viral drug therapy market are increasingly focusing on development and launch of combination drug therapy for treating HIV and other viral infections. Combination therapy involves the formulation of different drugs for treating different diseases. Combination therapy for treating viral infections has been proved effective in suppressing the replication of viruses and reducing antiviral resistance. In December 2019, Hetero, an India based pharmaceutical company launched an anti-retroviral combination drug consisting combination of drugs including Bictegravir (50mg), Emtricitabine (200mg), and Tenofovir Alafenamide (25mg) for treating patients with HIV. Also, in May 2020, a combination drug dose of Lopinavir/ritonavir which is already approved for treating HIV infection was approved for treating patients with COVID-19 by the Indian Council of Medical Research, India.
Global Research Initiatives And Funding-
Pharmaceutical companies and federal governments are increasingly working together in partnerships and collaborations to provide funding and implement incentive programs for the research and development (R&D) of anti-viral drugs. These partnerships provide financial and technical assistance across different clinical development phases to pharmaceutical companies. For instance, in July 2020, pharmaceutical companies like Novavax and Regeneron received billion funding from US federal government to manufacture drugs and vaccine against COVID-19. The Bill and Melinda Gates foundation with recipients including WHO, drug companies and governments together funded 5 million for drug development against COVID-19.
By Drug Class-
a. DNA (Nucleotide) Polymerase Inhibitors
b. Reverse Transcriptase Inhibitors
c. Protease Inhibitors
d. Neuraminidase Inhibitors
About The Business Research Company:
Like it? Share it!
About the Authorramacharitbrc
Joined: July 1st, 2020
Articles Posted: 1,235
More by this author